BCRX icon

BioCryst Pharmaceuticals

116 hedge funds and large institutions have $443M invested in BioCryst Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 23 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more call options, than puts

Call options by funds: $ | Put options by funds: $

more funds holding in top 10

Funds holding in top 10:

more ownership

Funds ownership:

1% more capital invested

Capital invested by funds: $439M → $443M (+$4.9M)

3% less funds holding

Funds holding: 120116 (-4)

17% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 23

Holders
116
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$907K
Puts
$577K
Net Calls
Net Calls Change

Top Buyers

1 +$15.3M
2 +$11M
3 +$10.8M
4
BlackRock
BlackRock
New York
+$4.88M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.58M

Top Sellers

1 -$7.31M
2 -$7.06M
3 -$3.36M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.71M
5
GTC
Ghost Tree Capital
New York
-$2.62M
Name Holding Trade Value Shares
Change
Change in
Stake
51
$464K
52
$402K
53
$377K
54
$349K
55
$349K
56
$342K
57
$332K
58
$324K
59
$289K
60
$287K
61
$275K
62
$267K
63
$261K
64
$258K
65
$241K
66
$211K
67
$211K
68
$207K
69
$207K
70
$184K
71
$170K
72
$164K
73
$155K
74
$151K
75
$150K